Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults - Concepedia

Concepedia

Publication | Open Access

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults

DOI Full Paper Access

237

Citations

39

References

2015

Year

Yvette L. Kasamon, Javier Bolaños‐Meade, Gabrielle T. Prince, Hua-Ling Tsai, Shannon R. McCurdy, Jennifer A. Kanakry, Gary L. Rosner, Robert A. Brodsky, Karlo Perica, B. Douglas Smith,

Journal of Clinical Oncology

Abstract

NMA haplo-BMT with post-transplantation cyclophosphamide has encouraging safety and survival outcomes in patients age 50 to 75 years. In patients otherwise fit for BMT, the results support consideration of this approach despite advanced age.

References

	Year	Citations

Page 1